CASI Pharmaceuticals, Inc. Major Shareholders & Ownership History
| Major Shareholder Name | Reporting Date | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| FEDERATED HERMES, INC. | 02/13/2023 | 900,651 | $1.58 M | -11.27% | 6.60% |
| VANGUARD GROUP INC | 02/10/2023 | 257,618 | $461,136 | 0.07% | 1.89% |
| GEODE CAPITAL MANAGEMENT, LLC | 02/13/2023 | 98,133 | $171,000 | -0.18% | 0.72% |
| BLACKROCK INC. | 02/13/2023 | 91,715 | $164,170 | 0.00% | 0.67% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 02/14/2023 | 57,395 | $100,441 | 70.63% | 0.42% |
| STATE STREET CORP | 05/15/2023 | 35,555 | $62,221 | 0.00% | 0.26% |
| NORTHERN TRUST CORP | 02/13/2023 | 25,593 | $45,811 | 0.00% | 0.19% |
| FRANKLIN RESOURCES INC | 02/10/2023 | 24,546 | $42,956 | 0.00% | 0.18% |
| DIMENSIONAL FUND ADVISORS LP | 02/09/2023 | 11,508 | $21,000 | 0.00% | 0.08% |
| RENAISSANCE TECHNOLOGIES LLC | 02/13/2023 | 10,900 | $20,000 | 4.81% | 0.08% |
| TOWER RESEARCH CAPITAL LLC (TRC) | 02/10/2023 | 3,494 | $7,000 | 51.58% | 0.03% |
| MORGAN STANLEY | 02/14/2023 | 1,946 | $3,483 | -51.04% | 0.01% |
| UBS GROUP AG | 02/08/2023 | 1,423 | $2,547 | -53.93% | 0.01% |
| WELLS FARGO & COMPANY/MN | 02/13/2023 | 62 | $111 | 100.00% | 0.00% |
| ROYAL BANK OF CANADA | 02/14/2023 | 58 | $0 | 222.22% | 0.00% |
| JPMORGAN CHASE & CO | 02/13/2023 | 25 | $0 | 0.00% | 0.00% |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 02/21/2023 | 13 | $23 | 100.00% | 0.00% |
| BANK OF AMERICA CORP /DE/ | 02/10/2023 | 12 | $21 | 100.00% | 0.00% |
| IFP ADVISORS, INC | 02/07/2023 | 9 | $1,000 | 0.00% | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 01/30/2023 | 0 | $0 | 0.00% | 0.00% |
| PRUDENTIAL FINANCIAL INC | 02/14/2023 | 0 | $0 | -100.00% | 0.00% |
| BNP PARIBAS ARBITRAGE, SNC | 02/14/2023 | 0 | $0 | -100.00% | 0.00% |
| ADVISOR GROUP HOLDINGS, INC. | 02/10/2023 | 0 | $0 | -100.00% | 0.00% |
CASI Pharmaceuticals, Inc.institutional Ownership - FAQ's
What percentage of CASI Pharmaceuticals, Inc. stock is owned by
institutional investors?
11.14% of CASI Pharmaceuticals, Inc. stock is owned by institutional investors.